Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More

Singapore Clinical Trial: A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants

Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability ... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More

Singapore Clinical Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More

NYT Spelling Bee Answers - July 28, 2026

New Delhi, July 28 -- The center letter for today's NYT Spelling Bee (July 28, 2026) is M. The outer letters are D, E, G, I, N, and P. There are three pangrams, IMPEDING, IMPENDING, and IMPINGED, all ... Read More

Contexto Answer Today - July 28, 2026 (#1409)

New Delhi, July 28 -- The Contexto answer for July 28, 2026 (#1409) is STORK. Three hints before the reveal for solvers still working toward the answer. Hint 1: Legendary deliverer of life's most pr... Read More

CJP threatens fresh nationwide stir, says SC order could be 'weaponised' against protesters

India, July 28 -- The Cockroach Janta Party (CJP) on Tuesday threatened to relaunch its nationwide agitation, alleging that a Supreme Court order allowing investigations into existing FIRs could be "w... Read More

Mancini returns for second spell as Italy coach

ROME, July 28 -- Roberto Mancini has been appointed for a second spell as Italy head coach, Italian Football Federation (FIGC) President Giovanni Malago announced on Tuesday. The 61-year-old succeeds... Read More

Commonwealth Games 2026 Day 5 India Results: Sharmila Dhankar Wins Gold As India Bag Six Medals-Full Medal Winners List And Highlights From July 27

India, July 28 -- It was a sensational day for India at the Commonwealth Games 2026 on July 27. Day 5 turned into a brilliant medal fest as Indian athletes claimed six medals in total: 1 Gold, 3 Silve... Read More

Singapore Clinical Trial: A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With Advanced EGFR-Mutated, Osimertinib-Resistant Non–Small Cell Lung Cancer (NSCLC)

Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With Ad... Read More

• ««
• «
• 10576
• 10577
• 10578
• 10579
• 10580
• 10581
• 10582
• 10583
• 10584
• 10585
• »
• »»